EIF4A2 and acute myeloid leukemia: In particular, we place this mechanism of RBM17-directed control upstream of the essential process of protein synthesis in LSC and identify inhibition of the RBM17-EIF4A2 axis as a potential therapeutic avenue for AML treatment.